2007: Antiphospholipid Syndrome

Antiphospholipid Syndrome

Saturday, November 10, 2007

1387

Risk Factors for the First Thrombotic Event in Antiphospholipid Antibody Carriers: A Multicenter Retrospective Follow-up Study

1388

Persistently Positive Antiphospholipid Antibodies are Related with the Appearance of Thrombosis During Follow-Up of Patients with Antiphospholipid Syndrome

1389

Prothrombotic Genetic Factors are Not Associated with Thrombosis in Patients with Antiphospholipid Syndrome

1390

Endogenous Thrombin Potential (ETP) in the Assessment of Hypercoagulability in SLE

1391

Impact of Hypertension and Hyperhomocysteinemia on Arterial Thrombosis in Primary Antiphoaspholipid Syndrome

1392

Bone Mineral Density Decreases in the Presence of Anticardiolipin Antibodies

1393

Leg ulcers in the Antiphospholipid Syndrome as a Form of Pyoderma Gangrenosum and Their Respond to Immunosuppressive Therapy and Anticoagulation

1394

Coronary Artery Disease Associated with Antiphospholipid Syndrome. Report of 25 Cases

1395

Cardiac Valve Replacement in APS Patients

1396

A Longitudinal Study of Antiphospholipid Antibodies in Women at Risk of Preeclampsia

1397

Relapsing Catastrophic Antiphospholipid Syndrome: Potential Role of Microangiopathic Hemolytic Anemia in Disease Relapses

1398

Practice Questions/Answers about Antiphospholipid Syndrome Pregnancies

1399

Innate Immunity and Antiphospholipid Syndrome: Prevalence and Clinical Significance of Polymorphisms of Mannose-Binding Lectin (mbl) and Toll-Like Receptors (tlr) 2 and 4

1400

Tyrosine Kinase 2 and Interferon Regulatory Factor 5 Gene Polymorphisms in Patients with Systemic Lupus Erythematosus and Antiphospholipid Syndrome

1401

Aminophospholipid Translocase (ATP10A) Polymorphisms and the Risk of Thrombosis in Patients with Antiphospholipid Antibodies

1402

Factor XIII Val34Leu Polymorphism is Associated to the Risk of Thrombosis in Patients with Antiphospholipid Antibodies and High Fibrinogen Levels

1403

Platelet Glycoprotein Ib-alpha, IIa/IIIa and IIb/IIIa Polymorphisms and Vascular Arterial Disease in Patients with the Antiphospholipid Syndrome or with Systemic Lupus Erythematosus

1404

Pro-inflammatory Genotype as a Risk Factor for Aps Clinical Manifestations: A Case Report

1405

Evidence for Interaction of B2-Glycoprotein I (β2GPI) with CD40 Ligand (CD40L): Their Role in the Pathogenesis of Antiphospholipid Syndrome (APS)

1406

The P38 Mitogen-Activate Protein Kinase (mapk) Pathway Mediates the Induction of Tissue Factor Expression by a Phosphatidylserine-Dependent Monoclonal Antiprothrombin Antibody with Lupus Anticoagulant Activity

1407

β2-Glycoprotein I Bound to Anionic Substance is a Preferential Target Recognized by Both Autoantibodies and Autoreactive T Cells in Patients with Antiphospholipid Syndrome

1408

Sequence Motifs in Human Monoclonal Antiphospholipid Antibodies Determine Their Ability to Bind but do not Effect the Function of Antigens Relevant to the Pathogenesis of Atherosclerosis in the Antiphospholipid Syndrome

1409

INF alpha Accelerates Nephritis, But Not Antiphospholipid Syndrome In NZW/BXSB F1 Females

1410

Pathogenic Effects of A Dimer of β₂glycoprotein I

1411

Decreased Paraoxonase Activity is Associated with Preclinical Atherosclerotic Vascular Changes in Primary Antiphospholipid Syndrome:

1412

Effects of an Inhibitor of Nuclear Factor-Kappa B (NF-κB) on Thrombogenic Properties of Antiphospholipid Antibodies in vivo.

See more of: ACR Abstract Submission Poster Sessions

<< Previous Session Level | Next Session Level >>